
pmid: 28637922
The phase 2 MAHALO clinical trial shows that lampalizumab reduces geographic atrophy secondary to age-related macular degeneration and implicates complement dysregulation in disease pathogenesis.
Male, Complement Pathway, Alternative, Middle Aged, Immunoglobulin Fab Fragments, Macular Degeneration, Geographic Atrophy, Disease Progression, Humans, Complement Factor D, Female, Aged
Male, Complement Pathway, Alternative, Middle Aged, Immunoglobulin Fab Fragments, Macular Degeneration, Geographic Atrophy, Disease Progression, Humans, Complement Factor D, Female, Aged
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 174 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
